SWP
JAZZ icon

Stratos Wealth Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Stratos Wealth Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,460
Closed -$437K – 1226
2021
Q2 		$437K Buy
2,460
+170
+7% +$29.4K 0.01% 820
2021
Q1 		$376K Buy
2,290
+114
+5% +$18.8K 0.01% 805
2020
Q4 		$359K Buy
+2,176
New +$324K 0.01% 784
2018
Q4 		– Sell
-631
Closed -$106K – 1672
2018
Q3 		$106K Buy
+631
New +$109K ﹤0.01% 1096
2018
Q2 		– Sell
-631
Closed -$95K – 1795
2018
Q1 		$95K Buy
+631
New +$92.6K ﹤0.01% 1234

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Stratos Wealth Partners's JAZZ Position: Q3 2021 in Review

Stratos Wealth Partners sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2021, closing a stake of 2,460 shares — an estimated $437K sold.

Stratos Wealth Partners first reported a position in JAZZ in Q1 2018 and held it in 5 quarters. The position peaked at $437K in Q2 2021. 455 funds tracked by Wall St. Rank hold JAZZ as of Q3 2021.

  • Stratos Wealth Partners reported no remaining Jazz Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Stratos Wealth Partners sold 2,460 Jazz Pharmaceuticals shares in Q3 2021, an estimated $437K.
  • Stratos Wealth Partners first reported a position in Jazz Pharmaceuticals in Q1 2018 and held it in 5 quarters.
  • Stratos Wealth Partners's Jazz Pharmaceuticals position peaked at $437K in Q2 2021.
  • 455 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2021.

Based on Stratos Wealth Partners's 13F filing for Q3 2021, filed 19 Oct 2021.